L3VLUP
ProSign in

CHRS · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CHRSAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CHRS
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterCHRSAMGN
Q3 20203 holders, $86m16 holders, $16.3bn
Q4 20204 holders, $85m19 holders, $14.0bn
Q1 20213 holders, $3.3m16 holders, $14.5bn
Q2 20213 holders, $3.1m23 holders, $13.8bn
Q3 20211 holders, $26k24 holders, $11.6bn
Q4 20214 holders, $95m21 holders, $10.4bn
Q1 20223 holders, $78m23 holders, $9.9bn
Q2 20221 holders, $10k28 holders, $9.7bn
Q3 20222 holders, $59m21 holders, $7.9bn
Q4 20221 holders, $13k24 holders, $9.3bn
Q1 20232 holders, $778k22 holders, $8.4bn
Q2 20231 holders, $2.1m26 holders, $7.4bn
Q3 20233 holders, $2.2m26 holders, $8.7bn
Q4 20232 holders, $3.6m24 holders, $8.4bn
Q1 20242 holders, $3.0m25 holders, $6.7bn
Q2 20241 holders, $558k20 holders, $8.0bn
Q3 2024none listed holders, n.a.21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 2025none listed holders, n.a.25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
CHRS

Coherus Oncology Inc

Holders
2
Reported value
$3.6m
Buyers
1
Sellers
1

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
24
Reported value
$8.4bn
Buyers
14
Sellers
11

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 24 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CHRS (0)

None.

Only AMGN (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Moore Capital Management LP, Neuberger Berman Group LLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →